Fresenius Medical Care returns to Dax 40 Index
Rhea-AI Summary
Fresenius Medical Care (FME), the world's leading provider of kidney disease products and services, will return to Germany's DAX 40 index on December 27, 2024. The DAX 40 represents the 40 largest companies on the Frankfurt Stock Exchange, accounting for 80% of Germany's listed stock market capitalization.
FME has been listed in the Mid-Cap DAX (MDAX) since March 2023, after being a DAX member from September 1999. The company operates 3,732 dialysis clinics, serving approximately 308,000 patients globally, and is a leading provider of dialysis equipment.
Positive
- Return to prestigious DAX 40 index, indicating improved market performance
- Market leadership position with 3,732 dialysis clinics globally
- Large patient base of 308,000 dialysis patients worldwide
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, FMS gained 1.47%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
BAD HOMBURG,
Helen Giza, CEO and Chair of the Management Board of Fresenius Medical Care AG, said: "We are delighted to return to the DAX 40. In
Fresenius Medical Care has been currently listed in the second-largest German stock market index, the Mid-Cap DAX (MDAX), which tracks the 50 largest companies below the DAX 40 since March 2023. Prior to this, the company had been a member of the DAX since September 1999.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,732 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 308,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company's website at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the
Media contact
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-returns-to-dax-40-index-302337459.html
SOURCE Fresenius Medical Care Holdings, Inc.